Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

(2020) David S Hong et al.   LANCET ONCOLOGY

CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells

(2020) Yingxiao Cao et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Ribociclib Drug‐Drug Interactions: Clinical Evaluations and Physiologically‐Based Pharmacokinetic Modeling to Guide Drug Labeling

(2020) Tanay S. Samant et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer

(2020) Aditya Bardia et al.   CLINICAL CANCER RESEARCH

Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.

(2019) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer

(2019) Richard S. Finn et al.   CLINICAL CANCER RESEARCH

Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study

(2019) Gwénaël Le Teuff et al.   PEDIATRIC BLOOD & CANCER

Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

(2019) Darren R. Hargrave et al.   CLINICAL CANCER RESEARCH

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

(2019) Robert C Doebele et al.   LANCET ONCOLOGY

Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium

(2017) Francisco Bautista et al.   EUROPEAN JOURNAL OF CANCER

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting

(2017) Julie R. Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

(2016) Yana Pikman et al.   CLINICAL CANCER RESEARCH

A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients

(2016) Nielka P. van Erp et al.   CLINICAL PHARMACOKINETICS

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs

(2015) Concepción Sánchez-Martínez et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations

(2014) M Moschetta et al.   BRITISH JOURNAL OF PHARMACOLOGY

Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines

(2014) Gerhard Hamilton et al.   MOLECULES

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies

(2014) Sarah K. Tasian et al.   Frontiers in Oncology

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study

(2013) Angela Di Giannatale et al.   EUROPEAN JOURNAL OF CANCER

A Direct Method for the Measurement of Everolimus and Sirolimus in Whole Blood by LC–MS/MS Using an Isotopic Everolimus Internal Standard

(2013) Phillip E. Morgan et al.   THERAPEUTIC DRUG MONITORING

Copy number defects of G1-Cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis

(2011) Jan J. Molenaar et al.   GENES CHROMOSOMES & CANCER

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound

(2009) Simona Caporali et al.   PHARMACOLOGICAL RESEARCH

Cyclin D1 and CDK4 Activity Contribute to the Undifferentiated Phenotype in Neuroblastoma

(2008) J. J. Molenaar et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER